FX.co ★ Kamada Confirms Full-year Revenue Outlook

Kamada Ltd. (KMDA), a biopharmaceutical firm, announced on Wednesday that it anticipates its full-year revenue to fall between $158 million and $162 million. The company maintains its expectations for adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) to be in the range of $32 million to $35 million for the year. Looking ahead to fiscal 2025, Kamada projects revenue between $178 million and $182 million, with adjusted EBITDA anticipated between $38 million and $42 million. The midpoint of the 2025 forecast indicates a rise of 13% in revenues and 19% in adjusted EBITDA compared to the midpoint of the 2024 estimates.